Latest studies
- Active not recruitingPHASE2
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
This study is for adults with bronchiectasis who were in a previous trial with the medicine BI 1291583. It aims to see if this medicine helps long-term and how well people tolerate it. Participants take tablets daily and visit the clinic regularly.
BronchiectasisLatvia - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Latvia - RecruitingPHASE1, PHASE2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
This study is testing a new medicine, LTP001, to see if it's safe and how it works in healthy people. Then, it will study people with a lung condition called Pulmonary Arterial Hypertension (PAH) to see if it helps them and if it's safe.
Healthy Volunteers, Pulmonary Arterial HypertensionLatvia - Active not recruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseLatvia - Enrolling by invitationPHASE3
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This study looks at a new drug, LP352, for children and adults with a type of epilepsy called Developmental and Epileopathic Encephalopathy (DEE). It checks how safe and effective the drug is over a longer period for those who have already started treatment in previous studies.
Developmental and Epileptic EncephalopathyLatvia - Active not recruitingPHASE3
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
This study is looking into a new medication called LP352 for children and adults with a severe type of epilepsy called Developmental and Epileptic Encephalopathies (DEE). It checks if LP352 can help reduce seizures and if it's safe to use. Some people will get LP352, others a dummy medicine.
Developmental and Epileptic EncephalopathyLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
This study is testing a new medicine, astegolimab, for people with a lung condition called COPD. It wants to see if this medicine can help reduce flare-ups (exacerbations) of COPD and if it's safe to use. You might get the new medicine or a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
This study is testing new treatments for COVID-19 in people who are at higher risk of becoming very unwell. It compares a new medicine called Bemnifosbuvir with usual care and Paxlovid to see if it helps prevent serious illness or hospital stays.
COVID-19Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS).
This study is looking at a new way to give eye injections for several common eye conditions that cause blurry vision. It's testing a pre-filled syringe of a drug called aflibercept to see how easy and safe it is to use. The aim is to make treatment simpler for patients.
Latvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma
This study looks at a new inhaler, CHF6001, for people with asthma that isn't fully controlled. Researchers want to see if adding this new inhaler to their usual medication helps reduce asthma attacks over 52 weeks and is safe.
AsthmaLatvia - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerLatvia - RecruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary DiseaseLatvia - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisLatvia - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsLatvia - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesLatvia - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusLatvia - Active not recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This study looks at a new medicine called ocrelizumab for children and teenagers aged 10-17 with a type of MS called relapsing-remitting multiple sclerosis (RRMS). It compares ocrelizumab to an existing medicine, fingolimod, to see how safe and effective it is over a period of time.
Relapsing-remitting Multiple SclerosisLatvia - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesLatvia - RecruitingPHASE3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
This study compares two treatments for a specific type of advanced lung cancer. It looks at how well a treatment combining sotorasib with chemotherapy works against one combining pembrolizumab with chemotherapy, focusing on extending life and preventing cancer growth.
Non-Small Cell Lung Cancer (NSCLC)Latvia - Active not recruitingPHASE2
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
This study is looking into a new drug called anvumetostat for people with a specific type of advanced lung cancer (NSCLC) that's missing a gene called MTAP. We want to see how safe the drug is and if it helps by slowing down or shrinking the cancer.
MTAP-deleted NSCLCLatvia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
This study looks at a medicine called Panzyga to see if it can prevent serious infections in people with certain autoimmune conditions. Participants receive either Panzyga or a salt solution to see if the medicine helps keep them healthier.
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.Latvia - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This study looks at the everyday safety and how well a drug called tolebrutinib is tolerated over a long time. It's for adults with different types of multiple sclerosis (MS) who have already been in earlier tolebrutinib studies.
Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisLatvia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
This study is looking into a new medicine, Zasocitinib, for people with psoriatic arthritis. It's checking its long-term safety and how well it helps their symptoms. Participants will either get Zasocitinib or a dummy medicine.
Psoriatic ArthritisLatvia - AuthorisedTherapeutic confirmatory (Phase III)
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
This study looks at a new drug, obrixtamig, alongside usual treatment for extensive small cell lung cancer. It aims to see if this new combination helps people live longer and feel better compared to the usual treatment alone.
small cell lung cancerLatvia - Active not recruitingPHASE3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
This study is testing a new injection treatment for house dust mite allergy. It aims to see if it reduces allergy symptoms and is safe for adults with moderate to severe allergic rhinitis, with or without asthma. The treatment is given over one year.
House Dust Mite AllergyHouse Dust Mite RhinitisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
This study is testing a new combination of treatments for advanced lung cancer. It combines a new drug, eftilagimod alfa, with existing treatments like pembrolizumab and chemotherapy, to see if it can help people live longer and improve their quality of life. Participants will be randomly assigned to different treatment groups.
Advanced/metastatic non-small cell lung cancer (NSCLC)Latvia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Latvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
This study looks at new treatments for advanced cancer with specific genetic changes. It combines two medicines, olaparib and pembrolizumab, to see how well they shrink tumours and improve outcomes for patients whose cancer has these particular genetic features.
The treatment of participants with HRRm and/or HRD-positive cancerLatvia - RecruitingPHASE2
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
The APEX study is looking at a new medicine called TX000045 for people with high blood pressure in their lungs caused by a certain type of heart failure. It will compare two doses of the medicine against a dummy treatment to see if it helps.
Pulmonary HypertensionHeart Failure With Preserved Ejection FractionLatvia - RecruitingPHASE2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It aims to see if the medicine is safe and helps improve symptoms compared to a dummy pill. It's a pill taken by mouth.
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active SevereLatvia - Recruiting
Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)
This study looks at how well a small heart monitor, called an Implantable Cardiac Monitor (ICM), works in real life for patients in the UK. It helps doctors understand its performance and safety over time, especially for conditions like irregular heartbeats or fainting spells.
TachycardiaAtrial FibrillationSyncopeBradycardiaLatvia - Active not recruitingPHASE3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
This study is testing a new medicine, povetacicept, for adults with a kidney condition called IgA Nephropathy. We want to see if it can help reduce protein in the urine and protect kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyLatvia - RecruitingPHASE2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
This study looks at new medications for adults with moderate to severe Crohn's disease. Researchers want to see how well these 'targeted therapies' work and if they cause side effects, to find better ways to manage the condition.
Crohn's DiseaseLatvia - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisLatvia - Active not recruitingPHASE3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This study is looking into the long-term safety and effectiveness of an inhaled medicine called seralutinib for adults with pulmonary arterial hypertension (PAH). Participants have already tried seralutinib in an earlier study and will continue to take it.
Pulmonary Arterial HypertensionLatvia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
This study looks at a new combination treatment for advanced lung cancer. It compares giving a well-known drug (pembrolizumab) with or without an additional drug (sacituzumab govitecan) to see which is better at slowing the cancer's growth and helping people live longer.
Carcinoma, Non-Small-Cell LungLatvia - Active not recruitingPHASE3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
This study is looking at a new medicine called sonelokimab for people with psoriatic arthritis who haven't tried powerful biologic drugs before. It wants to see if sonelokimab is safe and helps improve their arthritis and skin.
Arthritis, PsoriaticLatvia - Active not recruiting
BIOTRONIK Dynetic-35 Stent for the Treatment of Peripheral Iliac Lesions
This study tested a new stent called Dynetic-35 to treat blockages in blood vessels in the pelvis, which can cause leg pain. It looked at how safe and effective this new stent was for people with Peripheral Artery Disease.
Peripheral Artery DiseaseLatvia - AuthorisedPhase III and phase IV (Integrated)
“Study of pain syndrome and clinical-biochemical parameters in children aged 7 to 18 years in cases of non-surgical treatment of uncomplicated acute appendicitis”
This study looks at how a pain medicine, Ketorolac, works in children aged 7-18 with simple appendicitis that doesn't need surgery. Researchers are checking pain levels and body changes over 3 days.
uncomplicated acute appendicitisLatvia - RecruitingPHASE3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
This study is testing a new injection called Plozasiran for adults with very high triglyceride levels. Participants have already been in related studies and will receive the injection every three months for two years, while following a low-fat diet.
HypertriglyceridemiaLatvia - Enrolling by invitationNA
Optical Coherence Tomography in Acute Vessel Evaluation
This study compares two ways to help people having a heart attack: one uses standard X-rays, the other uses a special camera called OCT. We want to see if the OCT camera leads to better results for patients.
Ischemic Heart DiseaseIschemic Coronary Artery DiseaseACS (Acute Coronary Syndrome)Latvia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
This study looks at a new drug, claseprubart, for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see if the drug helps people with CIDP and if it's safe. Some participants will receive the drug, and others a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyLatvia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseLatvia - RecruitingPHASE2
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is looking at a new experimental drug, REGN13335, for adults with Pulmonary Arterial Hypertension (PAH). Researchers want to see if it's safe and effective when taken with other PAH medicines.
Pulmonary Arterial Hypertension (PAH)Latvia - Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
Multiple SclerosisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects with Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
This study is testing a new injection called PURETHAL Mites to see if it can help adults with hay fever-like symptoms or asthma caused by house dust mites. It compares the injection to a dummy treatment (placebo) to see if it reduces their allergy symptoms.
Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) AllergyLatvia - Active not recruiting
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
This study looks at the long-term safety of a medicine called Abatacept for children and teenagers with a type of arthritis called Juvenile Idiopathic Arthritis (JIA). Researchers want to see how safe it is over time, especially regarding serious infections, other immune problems, and cancer.
Juvenile Idiopathic ArthritisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
This study looks at the long-term safety and how well a medicine called soticlestat works for people with Dravet Syndrome or Lennox-Gastaut Syndrome. It's for those already in a previous study and focuses on side effects and overall health.
Dravet and Lennox-Gastaut SyndromesLatvia - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseLatvia - Recruiting
European Registry on the Management of Helicobacter Pylori Infection
This study is gathering information from doctors across Europe about how they treat H. pylori infection. It aims to understand current practices, check if guidelines are followed, and see what treatments work best to help improve care for patients with this common stomach infection.
H. Pylori InfectionLatvia